AXOGEN, INC. (NASDAQ:AXGN) Files An 8-K Other Events
Item 8.01Other Events
On January 15, 2019, AxoGen, Inc. (the “Company”) issued a press release announcing information regarding the Company’s RECON® study which supports its Biologic License Application Submission for Avance® Nerve Graft. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits
AxoGen, Inc. Exhibit
EX-99.1 2 axgn-20190115ex99168eb80.htm EX-99.1 Exhibit 991 Exhibit 99.1 AxoGen Announces RECON® Study Update Study Supports Company’s Planned Biologic License Application (BLA) for Avance® Nerve Graft ALACHUA,…
To view the full exhibit click here
